Posted on Apr 27, 2022
Pandemic updates: UW Medicine develops 'second-generation' Covid vaccine
574
7
2
5
5
0
Researchers at the University of Washington School of Medicine are boasting good news after a new Covid vaccine has shown positive results in its phase three trials.
Once again during this Covid pandemic, a new vaccine technology is making headlines. Unlike an mRNA vaccine, or other types that use an inactivated virus, this vaccine is protein based. To put it in more sciencey terms, it's a "computationally designed nanoparticle vaccine," and it's the first time such a technology has gone through phase three trials. UW Medicine calls it a "second-generation Covid-19 vaccine."
Researchers have dubbed their vaccine with the super catchy name of "GPB510." This vaccine is given in two doses, four weeks apart, similar to the Oxford/AstraZeneca vaccine which it was compared to during trials. However, GPB510 produced higher levels of protective antibodies in trials than the Oxford/AstraZeneca option.
Once again during this Covid pandemic, a new vaccine technology is making headlines. Unlike an mRNA vaccine, or other types that use an inactivated virus, this vaccine is protein based. To put it in more sciencey terms, it's a "computationally designed nanoparticle vaccine," and it's the first time such a technology has gone through phase three trials. UW Medicine calls it a "second-generation Covid-19 vaccine."
Researchers have dubbed their vaccine with the super catchy name of "GPB510." This vaccine is given in two doses, four weeks apart, similar to the Oxford/AstraZeneca vaccine which it was compared to during trials. However, GPB510 produced higher levels of protective antibodies in trials than the Oxford/AstraZeneca option.
Pandemic updates: UW Medicine develops 'second-generation' Covid vaccine
Posted from kuow.org
University of Washington
Medical
Health
Drugs
Pharmaceuticals
Posted 2 y ago
Responses: 2
0
0
0
PO1 William "Chip" Nagel some people don't have a positive bone in their body when it comes to the Covid vaccine... although they did take it. DUH!
..."A multinational Phase 3 trial involving 4,037 adults over 18 years of age found that the vaccine, dubbed GPB510, elicits higher levels of protective antibodies than the Oxford/AstraZeneca vaccine Vaxzevria. In these studies, GPB510 or Vaxzevria was administered twice with an interval of 4 weeks.
In addition, the ‘antibody conversion rate’, which refers to the proportion of subjects whose neutralizing antibody level increased fourfold or more after vaccination, was higher with GPB510.
T cell activation levels, which protect the body from COVID-19, were also similar or higher with GBP510.
Phase 1/2 trial results announced by SK bioscience this past November and posted as a preprint in March found that GPB510 was safe and produced virus-neutralizing antibodies in all trial participants receiving the adjuvanted vaccine. Today, April 25, SK bioscience issued a press release on its Phase 3 trial findings: SK bioscience Reports Positive Phase 3 Immunogenicity Results of Its Adjuvanted Covid-19 Vaccine Clinical Trial of COVID-19 Vaccine, AS03-adjuvanted.
Unlike the earliest approved vaccines for COVID-19 that make use of mRNA, viral vectors, or an inactivated virus, GPB510 is made of proteins that form tiny particles studded with fragments of the pandemic coronavirus. These nanoparticles were designed by scientists at UW Medicine and advanced into clinical trials by SK bioscience and GlaxoSmithKline with financial support from the Coalition for Epidemic Preparedness Innovations, also known as CEPI. GPB510 includes GSK’s pandemic adjuvant, AS03.
“This vaccine was designed at the molecular level to present the immune system with a key part of the coronavirus spike protein. We know this part, called the receptor-binding domain, is targeted by the most potent antibodies,” said Neil King, assistant professor of biochemistry at the University of Washington School of Medicine.
Two laboratories in the UW School of Medicine Department of Biochemistry led the initial development of the protein-based vaccine: the King Lab pioneered the vaccine’s self-assembling protein nanoparticle technology while the Veesler Lab identified and integrated a key fragment of the SARS-CoV-2 Spike protein onto the nanoparticles.
David Veesler, an associate professor of biochemistry and HHMI investigator at UW Medicine, has been studying coronaviruses since 2015. Using advanced electron microscopes, researchers in the Vessler lab were the first to identify how the novel coronavirus enters human cells. They were also among the first to report, in Cell, detailed structural information about the virus’ spike protein, a critical piece of its infectious machinery."...
..."A multinational Phase 3 trial involving 4,037 adults over 18 years of age found that the vaccine, dubbed GPB510, elicits higher levels of protective antibodies than the Oxford/AstraZeneca vaccine Vaxzevria. In these studies, GPB510 or Vaxzevria was administered twice with an interval of 4 weeks.
In addition, the ‘antibody conversion rate’, which refers to the proportion of subjects whose neutralizing antibody level increased fourfold or more after vaccination, was higher with GPB510.
T cell activation levels, which protect the body from COVID-19, were also similar or higher with GBP510.
Phase 1/2 trial results announced by SK bioscience this past November and posted as a preprint in March found that GPB510 was safe and produced virus-neutralizing antibodies in all trial participants receiving the adjuvanted vaccine. Today, April 25, SK bioscience issued a press release on its Phase 3 trial findings: SK bioscience Reports Positive Phase 3 Immunogenicity Results of Its Adjuvanted Covid-19 Vaccine Clinical Trial of COVID-19 Vaccine, AS03-adjuvanted.
Unlike the earliest approved vaccines for COVID-19 that make use of mRNA, viral vectors, or an inactivated virus, GPB510 is made of proteins that form tiny particles studded with fragments of the pandemic coronavirus. These nanoparticles were designed by scientists at UW Medicine and advanced into clinical trials by SK bioscience and GlaxoSmithKline with financial support from the Coalition for Epidemic Preparedness Innovations, also known as CEPI. GPB510 includes GSK’s pandemic adjuvant, AS03.
“This vaccine was designed at the molecular level to present the immune system with a key part of the coronavirus spike protein. We know this part, called the receptor-binding domain, is targeted by the most potent antibodies,” said Neil King, assistant professor of biochemistry at the University of Washington School of Medicine.
Two laboratories in the UW School of Medicine Department of Biochemistry led the initial development of the protein-based vaccine: the King Lab pioneered the vaccine’s self-assembling protein nanoparticle technology while the Veesler Lab identified and integrated a key fragment of the SARS-CoV-2 Spike protein onto the nanoparticles.
David Veesler, an associate professor of biochemistry and HHMI investigator at UW Medicine, has been studying coronaviruses since 2015. Using advanced electron microscopes, researchers in the Vessler lab were the first to identify how the novel coronavirus enters human cells. They were also among the first to report, in Cell, detailed structural information about the virus’ spike protein, a critical piece of its infectious machinery."...
(0)
(0)
0
0
0
Read This Next
Continue with Facebook 
Continue with Google